These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1212 related articles for article (PubMed ID: 18668517)

  • 1. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
    Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
    Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
    Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
    Kela I; Harmelin A; Waks T; Orr-Urtreger A; Domany E; Eshhar Z
    Prostate; 2009 Jul; 69(10):1034-44. PubMed ID: 19343735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of arginase II alters prostate tumor formation in TRAMP mice.
    Mumenthaler SM; Rozengurt N; Livesay JC; Sabaghian A; Cederbaum SD; Grody WW
    Prostate; 2008 Oct; 68(14):1561-9. PubMed ID: 18663728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
    Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
    Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
    Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
    Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
    Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
    Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
    J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
    Morgenbesser SD; McLaren RP; Richards B; Zhang M; Akmaev VR; Winter SF; Mineva ND; Kaplan-Lefko PJ; Foster BA; Cook BP; Dufault MR; Cao X; Wang CJ; Teicher BA; Klinger KW; Greenberg NM; Madden SL
    Prostate; 2007 Jan; 67(1):83-106. PubMed ID: 17013881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microarray-based expression profiling in prostate tumors.
    Elek J; Park KH; Narayanan R
    In Vivo; 2000; 14(1):173-82. PubMed ID: 10757075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
    Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
    Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
    Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
    Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling.
    Scaltriti M; Belloni L; Caporali A; Davalli P; Remondini D; Rizzi F; Astancolle S; Corti A; Bettuzzi S
    Carcinogenesis; 2006 May; 27(5):1047-53. PubMed ID: 16314398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6.
    Garcia GE; Wisniewski HG; Lucia MS; Arevalo N; Slaga TJ; Kraft SL; Strange R; Kumar AP
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):980-8. PubMed ID: 16467113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
    Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
    Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
    Tepaamorndech S; Huang L; Kirschke CP
    Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification.
    Ding Y; Xu L; Chen S; Jovanovic BD; Helenowski IB; Kelly DL; Catalona WJ; Yang XJ; Pins M; Ananthanarayanan V; Bergan RC
    Prostate Cancer Prostatic Dis; 2006; 9(4):379-91. PubMed ID: 16786039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
    Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
    Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
    Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
    Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model.
    Bethel CR; Bieberich CJ
    Prostate; 2007 Dec; 67(16):1740-50. PubMed ID: 17929276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.